



Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: the Way Forward for Successful Treatment

Brandon Lucke-Wold¹, Kay Seide², Rub Udo², Bennet Omalu³, Richard Nolan¹, Charles Rosen¹ and Joel S. Ross^{4*}

¹Department of Neurosurgery, West Virginia University School of Medicine, Morgantown, WV, USA

²Dr. Senckenberg Chronomedical Institute, J. W. Goethe University, Frankfurt am Main, Germany

³Department of Pathology, University of California Davis Medical Center, Davis, CA, USA

⁴Cogwellin LLC, 4 Industrial Way W, Eatontown NJ, USA

Abstract

Progressive neurodegenerative diseases plague millions of individuals both in the United States and across the world. Previous work has looked at tau hyperphosphorylation and amyloid deposits as key pathologic features in Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). Unfortunately, clinical trials targeting these disease mechanisms have continued to fail likely due to disease progression past a point of no return. In other words, the treatment trials have targeted a pathologic endpoint that no longer mediates the pivot towards recovery or decline. Recent evidence however suggests that pathologic changes start occurring early following neurologic insult and are mediated by mechanisms previously poorly understood. Secondary injury cascades such as oxidative stress, endoplasmic reticulum stress, and neuroinflammation contribute to lasting damage within the brain and can be induced by a number of different risk factors. These injury cascades funnel into a common pathway of early tau acetylation, which may serve as the catalyst for progressive degeneration. Prevention of tau acetylation could possibly serve as a novel target for stopping neurodegeneration before it fully begins. In this theoretical review, we highlight what is known about tau acetylation and neurodegeneration and show pathologic evidence that tau acetylation is an important component of both AD and CTE.

Keywords: Tau acetylation; Neurodegenerative diseases; Pathologic changes; Secondary injury cascades; Novel treatment target

Introduction

Tau hyperphosphorylation and amyloid plaques have long dominated the underlying dogma behind disease progression in Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). Multiple treatment strategies have been employed to prevent tau hyperphosphorylation or amyloid deposition. Unfortunately, these flawed hypotheses have failed to produce meaningful treatment options that can benefit patients. Our group and others have shown that looking earlier in the disease process may be more valuable in finding a treatment solution that can be clinically successful. Secondary injury mechanisms such as oxidative stress, endoplasmic reticulum stress, and neuroinflammation play a more important role in disease onset than previously assumed [1-4]. These secondary injury mechanisms can be primed by genetic predisposition and triggered by insults such as neurotrauma, drug abuse, and cardiovascular disease [5-7]. Once activated, these cascades lead to persistent damage to neurons and surrounding glia causing distinct tau acetylation [8]. It is at this crucial stage that the pivot point occurs on whether the brain recovers or progresses to neurodegeneration. Tau acetylation has been shown to both disengage tau from the microtubule and also facilitate tau aggregation [9]. Because of this, preventing tau acetylation is critical for stopping disease onset. Salsalate and methylene blue have both been shown to reduce tau acetylation in pre-clinical models, however the exact mechanism has not been fully elucidated [10]. It is likely that these drugs are limiting the expansion of secondary injury cascades following insult. In this review, we highlight the relationship of tau acetylation to AD and CTE and then discuss the most effective strategy for reducing tau acetylation via pharmaceutical intervention.

OPEN ACCESS

*Correspondence:

Joel S. Ross, Cogwellin LLC, 4 Industrial Way West, Eatontown, NJ 07724, Tel: 732.263.0101; 908.489.8760;

E-mail: jrossmd@cogwellin.com

Received Date: 25 Sep 2017


Accepted Date: 09 Jan 2018

Published Date: 12 Jan 2018

Citation:

Lucke-Wold B, Seidel K, Udo R, Omalu B, Nolan R, Rosen C, et al. Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: the Way Forward for Successful Treatment. *J Neurol Neurosurg Spine*. 2018; 3(1): 1012.

Copyright © 2018 Joel S. Ross. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Tau acetylation and AD

On November 3, 1906, Alois Alzheimer presented the first definitive microscopic evidence of the tau tangle pathology that has become characteristic of degenerative AD [11]. By using the same stain that Max Bielschowsky used 4 years earlier, he also described neuritic plaques that sparked the amyloid hypothesis years later. The pathology was accompanied by detailed clinical reports of progressive dementia for several years prior to death. These findings would set the framework of defining AD. In 1984 the amyloid protein was identified as the core of the neuritic plaque and the amyloid cascade hypothesis was born. Over the past 33 years scientists have been attempting to find safe and effective treatments to remove amyloid from the brains of AD patients. Pharmaceutical companies have been testing agents to slow production of amyloid as well as administering antibodies or vaccines to remove amyloid from the brains of AD patients. Sadly, every anti-amyloid study to date has failed [12].

Proponents of the amyloid hypothesis still hold out hope that if such agents are administered at the asymptomatic stage or at the very early mild cognitive impairment stage positive results with acceptable side effects might be achieved [13]. More recently there has been a shift to look at pathologic tau in the progression of AD. It is the location and amount of tau found on autopsy in AD subjects that correlates best with stage and severity of symptomatology, not the amyloid plaque [14]. As far back as 1963, such tangles were noted to be composed of filaments with a diameter of approximately 10 nm that have come to be known as Paired Helical Filaments (PHF) [15]. In 1992, Dreschel et al. [16], first reported on the structural importance of the micro-tubular associated protein, tau (Tubulin Associated Unit) in disease pathology.

It was at this point that research shifted towards understanding tau post-translational modifications. Normally tau has 83 potential sites of phosphorylation at various serine, threonine, and tyrosine sites of the 441 amino acid long tau protein. Excess p-tau is as high as 4-5x the normal level in the brain homogenates of AD brains when compared to control brains [17]. Because tau hyperphosphorylation was the first characterized, it garnered the most attention. In 1994, Khalid Iqbal was first to report that tau is a marker of neurofibrillary tangles in Alzheimer's Disease patients upon autopsy [18]. He and others noted that an excess phosphorylation (p-tau) of the human tau

protein could be pathological [17]. In subsequent studies of AD and related "abnormal" tau associated disorders such as corticobasilar degeneration, progressive supranuclear palsy, Picks disease and chronic traumatic encephalopathy, excess of tau phosphorylation have been consistently reported [19]. Recently however evidence has emerged that p-tau is not pathogenic and is not responsible for the loss of neuronal function in AD [20].

Tau Acetylation and CTE

CTE is a devastating neurodegenerative disease triggered by head injury. Like other tauopathies, it is progressive in nature and contributes to both cognitive and functional decline. Omalu and colleagues described the modern version of CTE in retired professional athletes [21]. The players had extensive histories of repetitive concussions followed by a series of impulsive events, cognitive decline, and frequently suicide. This original characterization of CTE sparked huge controversy and met resistance by sports organizations and scientists alike. Over the next decade, other groups validated the findings proposed by Omalu and began describing a very distinct pathologic paradigm [22]. Similar to Alzheimer's disease, the disease correlation was most in line with the tau progression.

Our group and others began looking towards secondary injury mechanisms that can contribute to tauopathy. Promising pre-clinical data pointed to the role of endoplasmic reticulum stress and oxidative stress in the pathophysiology of neurodegeneration following neurotrauma [2,23]. The exact mechanism by which this occurs however was not completely elucidated. We found that ER stress is increased in cells that are undergoing apoptosis as well as those that develop tauopathy [24]. The key markers that were increased were markers of tau hyperphosphorylation AT100, PHF, and CP-13 [25]. It is apparent that tau hyperphosphorylation is an end-stage marker. How these markers got increased and what maintained the progressive tauopathy is still under investigation. Kondo and colleagues proposed that cis tau might play a role [26]. Kaye and colleagues assert that it is more likely the tau oligomers [27]. We however have discovered an earlier contributor to the disease process.

The Tau Pathology Catalyst

The lack of correlation between tau phosphorylation and functional decline sparked interest in understanding which tau modification actually does contribute to pathology. Tau is a very soluble hydrophilic protein. Full-length tau remains soluble in solution up to 10000 mM before it can aggregate. The tau repeat domain needs a concentration in solution of 4000 mM to aggregate. High p-tau expressed in Sf9 cells (high phosphate) requires 200 mM before p-tau can aggregate. Since the concentration of p-tau in the CSF is 0.00002 picomolar, 0.001 nanomolar in the interstitial fluid, and 1.0 micromolar in the neurons, it would seem quite impossible to expect p-tau at the levels seen in human AD brains to aggregate without a catalyst. Thus, there must be a nucleating factor that acts as the "seed" which leads to the phosphorylation seen in the neurofibrillary tangle. A neurofibrillary tangle is composed of a "fuzzy coat" or "soft polymer brush" [28]. This coat surrounds the core of tau fibers and can bind multiple cell components. Inside the tangle is a rigid fibril core. There are spokes emanating out of the core where two post translationally modified protein motifs exist known as hexapeptide PHF6* and PHF6. PHF6* has the following amino acid sequence: V Q I N N K whereas PHF6 has the following amino acid sequence: V Q I V Y K. Both hexapeptides are in the microtubular binding domain (MTBD) portion of the tau protein and are thought to be essential for



Figure 2: Tau acetylation at K280 in the caudate, putamen, and thalamus.

the proper binding of tau onto the alpha and beta tubulin subunits of the microtubule [29].

Recent evidence suggests that a posttranslational acetylated modification of lysine at position 280 of the hexapeptide of the PHF6 can lead to pathological aggregation of tau [30]. Post mortem mass spectrometry analysis of AD brains has shown such acetylation occurs most specifically at lysine position 280. However, acetylation of lysine at positions 174, 274 and 281 has also been reported in other human tauopathies [31]. This acetylation may be due to the overactivity of the acetyltransferase enzyme p-300, which acts specifically on PHF6. Gorsky et al. [32] showed that even pseudo-acetylation of the single K280 residue by p-300 was able to exacerbate hTau neurotoxicity *in vivo*, which is suggestive that acetylated tau contributes to the pathology seen in neurodegenerative diseases.

After tau is acetylated, there is dislodgement of the microtubular binding domain from the tubulin due to the neutralization of charges between tau and tubulin molecules. This exposes the previously unphosphorylated serines/threonines/tyrosines to kinases leading to the robust phosphorylation so often seen in brain homogenates of AD and CTE patients. It is likely that the hyper-phosphorylation will only occur in the context of tau acetylation. In Irwin's seminal paper, there is co-localization of acetylated K280 with multiple p-tau epitopes in post-mortem AD brains [33]. Their study showed that acetylated K280 occurred early in the pathogenesis of neurodegeneration. Originally Braak and Braak indicated that phosphorylated tau in AD patients starts in the entorhinal and transentorhinal cortex and spreads up through the neocortex [34]. In 2012 Senanarong et al. [35] reported a very early occurrence of AD-related cytoskeletal changes

of p-tau in brainstem nuclei with likely spreading in a prion like manner (prionoid) up the white matter tracks to the neo/allocortex (Figure 1). We highlight below that tau acetylation occurs in these exact same regions.

Methods

Human paraffin embedded specimens were collected from post-mortem samples of the entorhinal cortex for CTE brains (N=3) and from the putamen, caudate, thalamus, brain stem, and cerebral white matter of AD brains (N=3). Brain slices were cut to 100µm thickness with a Leica RM2265 microtome (Leica Biosystems). The slides were soaked in 99% formic acid for 10 minutes. A tau acetylation antibody for K280 was utilized. (Anaspec, rabbit polyclonal antibody). Staining of AD brain slices was conducted by Udo Rub and Kay Seidel at their laboratory of Goethe-University, Frankfurt/Main, Germany. The antibody was used at a concentration of 1:200. The standardized method of staining with primary and secondary antibodies was performed as has previously been published [2]. CTE brains were co-stained with MC1, which was kindly gifted from Dr. Peter Davies. The CTE images were analyzed with the Just Another Co-localization plug-in from Image J. An overlap coefficient was generated for each overlay. $R > 0.8$ indicates strong correlation, $R = 0.6 - 0.8$ equals moderate correlation, $R = 0.4 - 0.6$ weak correlation, and $R < 0.4$ is minimal overlay.

Results

AD Brains

Three Braak stage 1 brains were stained with the tau K280 acetylation antibody. Significant staining was seen in the brain stem, caudate, and putamen (Figure 2). Slightly less staining was seen in the thalamus. Such early staining likely indicates the initial pathology in disease progression, which proceeds tau hyperphosphorylation. Similarly, staining was positive in the brainstem but was not seen in controls (Figure 3). Therefore, a strategy to slow tau acetylation seems plausible as a method to prevent disease onset and progression.

CTE Brains

Three CTE brains were stained and compared to controls. An overlay between acetylated tau K280 and MC1 was done. MC1 is an early marker of tau hyperphosphorylation seen in neurodegeneration. Figure 4 shows an overlap coefficient of $R = 0.33$, which indicates minimal co-staining for tau pathology in control brains. Figure 5 shows an overlap coefficient of $R = 0.97$, which indicates strong correlation for tau acetylation and hyperphosphorylation in the entorhinal cortex. The results show that tau acetylation is at least present at time of tau phosphorylation, but more likely precedes it.

Conclusion

Targeting tau phosphorylation has yielded little in terms of viable treatments for patients with neurodegeneration therefore urging a new strategy. Min and Gan from the Gladstone Institute tested the non-steroidal anti-inflammatory agent salsalate in pseudo-acetylated mice at a dose of 2250 grams per day. The results indicated significant improvement in cognitive function due to reduction in p-300 induced tau acetylation and reduced hippocampal atrophy [36]. Lagraoui et al. [37] further tested salsalate in a traumatic brain injury mouse model. Their report revealed that when salsalate was given post TBI there was a significant reduction in neuroinflammation, improved functional ability, as well as an upregulation of genes that are associated with neuroprotection and neurogenesis. The likely mechanism is salsalate




Figure 3: Tau acetylation at K280 in the brainstem of AD Braak Stage 1, but not seen in controls.

reducing ER stress and thereby limiting p-300 activity.

Going forward it is imperative to examine what actually drives disease pathogenesis. In this paper, we have outlined how tau acetylation plays a critical role in the process of neurodegeneration. Furthermore, we have shown that tau acetylation was increased both in human AD and CTE brain specimens. Future studies are warranted for how to target tau acetylation in order to prevent disease progression. It is likely that ER stress, oxidative stress, and neuroinflammation are the triggers that activate the tau acetylation process. Pre-clinical work should flush out the mechanisms at play in order to advance towards clinical trials for potential treatments. An interdisciplinary team of clinicians and scientists will be necessary to tackle this important work. Re-examining the tau hypothesis might be the paradigm shift needed for making headway on discovering new treatments for neurodegeneration.

Acknowledgement

Brandon Lucke-Wold received pre-doctoral support from the American Foundation of Pharmaceutical Education and American Association of Pharmaceutical Scientists.

References

1. Lucke-Wold BP, Naser ZJ, Logsdon AF, Turner RC, Smith KE, Robson MJ, et al. Amelioration of nicotinamide adenine dinucleotide phosphate-oxidase mediated stress reduces cell death after blast-induced traumatic brain injury. *Transl Res*. 2015;166(6):509-528.e1.
2. Lucke-Wold BP, Turner RC, Logsdon AF, Nguyen L, Bailes JE, Lee JM, et al. Endoplasmic reticulum stress implicated in chronic traumatic encephalopathy. *J Neurosurg*. 2016;124(3):687-702.
3. Turner RC, Lucke-Wold BP, Robson MJ, Lee JM, Bailes JE. Alzheimer's disease and chronic traumatic encephalopathy: Distinct but possibly overlapping disease entities. *Brain Inj*. 2016;30(11):1279-1292.
4. Remondelli P, Renna M. The Endoplasmic Reticulum Unfolded Protein Response in Neurodegenerative Disorders and Its Potential Therapeutic Significance. *Front Mol Neurosci*. 2017;10:187.
5. Armstrong RA, Mckee AC, Stein TD, Alvarez VE, Cairns NJ. A quantitative study of tau pathology in 11 cases of chronic traumatic encephalopathy. *Neuropathol Appl Neurobiol*. 2017;43(2):154-166.
6. Asken BM, Sullan MJ, Snyder AR, Houck ZM, Bryant VE, Hizel LP, et al. Factors Influencing Clinical Correlates of Chronic Traumatic

Encephalopathy (CTE): a Review. *Neuropsychol Rev*. 2016;26(4):340-363.

7. Lucke-Wold BP, Turner RC, Logsdon AF, Simpkins JW, Alkon DL, Smith KE, et al. Common mechanisms of Alzheimer's disease and ischemic stroke: the role of protein kinase C in the progression of age-related neurodegeneration. *J Alzheimers Dis*. 2015;43(3):711-24.
8. Marcelli S, Corbo M, Iannuzzi F, Negri L, Blandini F, Nistico R, et al. The Involvement of Post-Translational Modifications in Alzheimer's Disease. *Curr Alzheimer Res*. 2017.
9. Trzeciakiewicz H, Tseng JH, Wander CM, Madden V, Tripathy A, Yuan CX, et al. A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy. *Sci Rep*. 2017;7:44102.
10. Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, et al. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. *Biomed Res Int*. 2016;2016:3245935.
11. Zilka N, Novak M. The tangled story of Alois Alzheimer. *Bratisl Lek Listy*. 2006;107(9-10):343-5.
12. Ricciarelli R, Fedele E. The amyloid cascade hypothesis in Alzheimer's disease: it's time to change our mind. *Curr Neuropharmacol*. 2017;15(6):926-935.
13. Okazawa H. Ultra-Early Phase pathologies of Alzheimer's disease and other neurodegenerative diseases. *Proc Jpn Acad Ser B Phys Biol Sci*. 2017;93(6):361-77.
14. Sabbagh MN, Lue LF, Fayard D, Shi J. Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data. *Neurol Ther*. 2017;6(Suppl 5):83-95.
15. Kurt MA, Davies DC, Kidd M, Duff K, Howlett DR. Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. *Neurobiol Dis*. 2003;14(1): 89-97.
16. Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. *Mol Biol Cell*. 1992;3(10):1141-54.
17. Khatoon S, Grundke-Iqbal I, Iqbal K. Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. *FEBS Lett*. 1994;351(1):80-4.
18. Tatebayashi Y, Haque N, Tung YC, Iqbal K, Grundke-Iqbal I. Role of tau phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport. *J Cell Sci*. 2004;117(Pt 9):1653-63.
19. Lee VM, Brunden KR, Hutton M, Trojanowski JQ. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. *Cold Spring Harb Perspect Med*. 2011;1(1): a006437.
20. Lai RY, Harrington CR, Wischik CM. Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease. *Biomolecules*. 2016;6(2).
21. Omalu BI, Dekosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH. Chronic traumatic encephalopathy in a National Football League player. *Neurosurgery*. 2005;57(1):128-34.
22. Mckee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. *J Neuropathol Exp Neurol*. 2009;68(7):709-35.
23. Logsdon AF, Lucke-Wold BP, Nguyen L, Matsumoto RR, Turner RC, Rosen CL, et al. Salubrinal reduces oxidative stress, neuroinflammation and impulsive-like behavior in a rodent model of traumatic brain injury. *Brain Res*. 2016;1643:140-51.
24. Lucke-Wold BP, Logsdon AF, Turner RC, Huber JD, Rosen CL. Endoplasmic Reticulum Stress Modulation as a Target for Ameliorating Effects of Blast Induced Traumatic Brain Injury. *J Neurotrauma*. 2017;34(S1):S62-S70.

25. Turner RC, Lucke-Wold BP, Logsdon AF, Robson MJ, Dashnaw ML, Huang JH, et al. The Quest to Model Chronic Traumatic Encephalopathy: A Multiple Model and Injury Paradigm Experience. *Front Neurol.* 2015;6:222.
26. Kondo A, Shahpasand K, Mannix R, Qiu J, Moncaster J, Chen CH, et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. *Nature.* 2015;523:431-36.
27. Gerson J, Castillo-Carranza DL, Sengupta U, Bodani R, Prough DS, Dewitt DS, et al. Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice. *J neurotrauma.* 2016;33(22):2034-43.
28. Pickhardt M, Biernat J, Hubschmann S, Dennissen FJA, Timm T, Aho A, et al. Time course of Tau toxicity and pharmacologic prevention in a cell model of Tauopathy. *Neurobiol Aging.* 2017;57:47-63.
29. Von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM, et al. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. *J Biol Chem* 2001;276(51):48165-74.
30. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. *Nat Commun.* 2011;2:252.
31. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. *Neuron.* 2010;67:953-66.
32. Gorsky MK, Burnouf S, Dols J, Mandelkow E, Partridge L. Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity *in vivo*. *Sci Rep.* 2016;6:22685.
33. Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM, et al. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. *Brain.* 2012;135(Pt 9):807-18.
34. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* 1991;82(4): 239-59.
35. Senanarong V, Siwasariyanon N, Washirutmangkur L, Pongvarin N, Ratanabunakit C, Aoonkaew N, et al. Alzheimer's disease dementia as the diagnosis best supported by the cerebrospinal fluid biomarkers: difference in cut-off levels from thai experience. *Int J Alzheimers Dis.* 2012;2012:212063.
36. Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. *Nat Med.* 2015;21(10):1154-62.
37. Lagraoui M, Sukumar G, Latoche JR, Maynard SK, Dalgard CL, Schaefer BC. Salsalate treatment following traumatic brain injury reduces inflammation and promotes a neuroprotective and neurogenic transcriptional response with concomitant functional recovery. *Brain Behav Immun.* 2017;61:96-109.